Results 231 to 240 of about 24,223,577 (293)

Antimicrobial Peptides SET-M33L and SET-M33L-PEG Are Promising Agents Against Strong Biofilm-Forming <i>P. aeruginosa</i>, Including Multidrug-Resistant Isolates. [PDF]

Antibiotics (Basel)
Fontanot A, Croughs PD, Cortese C, de Bruijn ACJM, Falciani C, Pini A, Ellinger I, Unger WWJ, Hays JP.   +8 more
europepmc   +1 more source

Citric Acid‐Crosslinked Chitosan Coatings Incorporating Curcumin for Enhancement of Antioxidant and Antimicrobial Properties

Journal of Vinyl and Additive Technology, EarlyView.
A fully bio‐based coating was developed using Chitosan, Citric acid, and Curcumin. Citric acid acts simultaneously as a green solvent and non‐toxic crosslinker. Dry Heat Treatment enhances water resistance and thermal stability, creating an active packaging system with dual antioxidant and antimicrobial properties to extend food shelf‐life.
Miriam Cappello, Cheherazade Trouki, Niccoletta Barbani, Maria J. Lopez, Ana J. Toribio‐Gallardo, Caterina Cristallini, Neetu Malik, Damiano Rossi, Maurizia Seggiani, Patrizia Cinelli   +9 more
wiley   +1 more source

Quorum Quenching of <i>P. aeruginosa</i> by <i>Portulaca oleracea</i> Methanolic Extract and Its Phytochemical Profile. [PDF]

Pathogens
Al-Daghistani HI, Matalqah SM, Shadid KA, Abu-Niaaj LF, Zein S, Abo-Ali RM.   +5 more
europepmc   +1 more source

Clinical Features and Outcomes of Chronic Otitis Media Complications: A 20‐Year Retrospective Study at a Tertiary Hospital

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Chronic otitis media (COM) is a major public health concern, particularly in developing countries. Although complications have decreased with modern antibiotics, they still cause significant morbidity and mortality. This study analyzed the clinical features, bacteriological profiles, and treatment outcomes of COM complications at a ...
Viraporn Atchariyasathian, Nipit Tangchitnob   +1 more
wiley   +1 more source

174 Garlic which blocks the P. aeruginosa QS systems, promotes rapid clearing of pulmonary P. aeruginosa infections

Journal of Cystic Fibrosis, 2005
openaire   +1 more source

SPECT Imaging of P. aeruginosa Infection in Mice Using ¹²³I-BMIPP. [PDF]

Pharmaceutics
Nishiyama Y, Mizutani A, Kobayashi M, Muranaka Y, Sato K, Maki H, Kawai K.   +6 more
europepmc   +1 more source

In Vitro and In Vivo Evaluation of the De Novo Designed Antimicrobial Peptide P6.2 Against a KPC-Producing <i>P. aeruginosa</i> Clinical Isolate. [PDF]

Biomolecules
Martinez MMB, Corleto M, Weschenfeller M, Urrea Montes S, Salomón CN, Gonzalez N, Garavaglia M, Faccone D, Maffía PC.   +8 more
europepmc   +1 more source

Development and Characterization of LasR Immobilized Monolithic Column for Screening Active Ingredients as Quorum Sensing Inhibitors Against <i>P. aeruginosa</i> in Natural Products. [PDF]

Drug Des Devel Ther
Liu Z, Yang Y, Xie X, Li R, You J, Zhao X, Wang Y, Guo J.   +7 more
europepmc   +1 more source

Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats. [PDF]

Respir Res
Keith JD, Murphree-Terry M, Bollar G, Oden AM, Doty IH, Birket SE.   +5 more
europepmc   +1 more source